Washington, D.C. 20549
Pursuant to Section 13 OR 15(d) of The
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): June 26, 2023
Axonics, Inc.
(Exact name of registrant as specified in its charter)
Delaware 001-38721 45-4744083
(State or other jurisdiction
of incorporation)
 (Commission File Number) (I.R.S. Employer
Identification No.)
26 Technology Drive
Irvine, California 92618
(Address of principal executive offices) (Zip Code)
(949) 396-6322
(Registrant’s telephone number, including area code)
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Exchange Act:
Title of classTrading symbolName of exchange on which registered
Common stock, par value $0.0001 per shareAXNXNasdaq Global Select Market
Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐

Item 5.07.    Submission of Matters to a Vote of Security Holders.
Axonics, Inc. (the “Company”) held its Annual Meeting of Stockholders (the “Annual Meeting”) on June 26, 2023. On April 27, 2023, the record date (the “Record Date”) for determining stockholders entitled to vote at the Annual Meeting, there were 50,383,730 shares of the Company’s common stock, par value $0.0001 per share (“Common Stock”) outstanding. Holders of 44,438,263 shares of Common Stock (representing 88% of the shares of Common Stock outstanding on the Record Date) were present or represented by proxy at the Annual Meeting, constituting a quorum. During the Annual Meeting, the stockholders of the Company voted on three proposals described in the Company’s definitive proxy statement on Schedule 14A filed with the Securities and Exchange Commission on May 1, 2023. The results for each matter voted on by the stockholders during the Annual Meeting were as follows:

Proposal 1: The stockholders of the Company elected Raymond W. Cohen, Robert E. McNamara, Michael H. Carrel, Nancy Snyderman, M.D., FACS, Jane E. Kiernan, David M. Demski, and Esteban López, M.D. to the Board of Directors, each for a one-year term ending at the Annual Meeting of Stockholders to be held in 2024 and until their successor has been duly elected and qualified, or until their earlier death, resignation or removal. The results of the stockholders’ vote with respect to the election of the directors were as follows:

NomineeTerm ExpiringForAgainstAbstain
Raymond W. Cohen202442,047,299739,61211,653
Robert E. McNamara202438,219,1374,568,40111,026
Michael H. Carrel202440,366,2052,421,17811,181
Nancy Snyderman, M.D., FACS202437,561,3485,225,86611,350
Jane E. Kiernan202441,242,7611,544,30511,498
David M. Demski202442,048,412739,15510,997
Esteban López, M.D.202438,335,8334,432,11430,617

Broker Non-Votes: 1,639,699

Proposal 2: The stockholders of the Company ratified the appointment of BDO USA, LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023. The results of the stockholders’ vote with respect to such ratification were as follows:


Proposal 3: The stockholders of the Company approved, on an advisory basis, the compensation of the named executive officers of the Company. The results of the stockholders’ vote with respect to such approval were as follows:


Broker Non-Votes: 1,639,699

Item 9.01.    Financial Statements and Exhibits.
    (d) Exhibits.
Exhibit No.Description
104Cover Page Interactive Date File - the cover page XBRL tags are embedded within the Inline XBRL document.

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: June 27, 2023 By: /s/ Raymond W. Cohen
  Raymond W. Cohen
  Chief Executive Officer